These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15564236)

  • 1. FDA is incapable of protecting US "against another Vioxx".
    Lenzer J
    BMJ; 2004 Nov; 329(7477):1253. PubMed ID: 15564236
    [No Abstract]   [Full Text] [Related]  

  • 2. The Vioxx debacle revisited.
    Manthous CA
    Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
    [No Abstract]   [Full Text] [Related]  

  • 3. The Vioxx debacle revisited.
    Mohapatra PR; Janmeja AK
    Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
    [No Abstract]   [Full Text] [Related]  

  • 4. The vexations of Vioxx.
    Sibbald B
    CMAJ; 2006 Feb; 174(4):444-5. PubMed ID: 16477046
    [No Abstract]   [Full Text] [Related]  

  • 5. Vioxx: lessons for Health Canada and the FDA.
    CMAJ; 2005 Jan; 172(1):5, 7. PubMed ID: 15632383
    [No Abstract]   [Full Text] [Related]  

  • 6. New use approved for Vioxx.
    FDA Consum; 2002; 36(4):3. PubMed ID: 12184302
    [No Abstract]   [Full Text] [Related]  

  • 7. Crisis deepens at the US Food and Drug Administration.
    Lenzer J
    BMJ; 2004 Dec; 329(7478):1308. PubMed ID: 15576741
    [No Abstract]   [Full Text] [Related]  

  • 8. Despite warnings, drug giant took long path to Vioxx recall.
    Berenson A; Harris G; Meier B; Pollack A
    N Y Times Web; 2004 Nov; ():A1, A32. PubMed ID: 15599982
    [No Abstract]   [Full Text] [Related]  

  • 9. Merck withdraws Vioxx; FDA issues public health advisory.
    FDA Consum; 2004; 38(6):11. PubMed ID: 15675020
    [No Abstract]   [Full Text] [Related]  

  • 10. How to avoid future Vioxx-type scandals.
    Prescrire Int; 2005 Jun; 14(77):115-7. PubMed ID: 15984108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rofecoxib, Merck, and the FDA.
    Kim PS; Reicin AS
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
    [No Abstract]   [Full Text] [Related]  

  • 12. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

  • 13. Vioxx may go back on sale after scraping past FDA panel.
    Wadman M
    Nature; 2005 Feb; 433(7028):790. PubMed ID: 15729304
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 15. What ails the FDA?
    Cohen FJ
    N Engl J Med; 2005 Jun; 352(24):2554. PubMed ID: 15962406
    [No Abstract]   [Full Text] [Related]  

  • 16. What ails the FDA?
    Gorelick KJ
    N Engl J Med; 2005 Jun; 352(24):2553-4. PubMed ID: 15958814
    [No Abstract]   [Full Text] [Related]  

  • 17. Rofecoxib, Merck, and the FDA.
    Wolfe MM
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
    [No Abstract]   [Full Text] [Related]  

  • 18. Avoiding another Vioxx.
    Beardsley S
    Sci Am; 2005 Feb; 292(2):16, 18. PubMed ID: 15715381
    [No Abstract]   [Full Text] [Related]  

  • 19. The sad story of Vioxx, and what we should learn from it.
    Karha J; Topol EJ
    Cleve Clin J Med; 2004 Dec; 71(12):933-4, 936, 938-9. PubMed ID: 15641522
    [No Abstract]   [Full Text] [Related]  

  • 20. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.